Key facts
- This page summarizes Andrew Paul Mazar's Form 3 filing for ACTUATE THERAPEUTICS, INC. (ACTU).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Aug 2024, 21:47.
Andrew Paul Mazar - 12 Aug 2024 Form 3 Insider Report for ACTUATE THERAPEUTICS, INC. (ACTU)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- ACTU
- Reported as of
- 12 Aug 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 12 Aug 2024, 21:47:05 UTC
- Prior SEC filing
- 01 Apr 2022
- Next SEC filing
- 02 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paul Lytle, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Andrew Paul Mazar filed Form 3 for ACTUATE THERAPEUTICS, INC. (ACTU) on 12 Aug 2024.
Change
- Previous filing in this sequence was filed on 01 Apr 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACTU
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 127,250
- Date
- 12 Aug 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACTU
holding
Derivative
Non-Qualified Stock Options
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 12 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,374
- Exercise price
- $2.14
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Includes 27,778 restricted common stock awards that were granted on February 22, 2021, of which, 25% vested on the first anniversary of the grant date and the remaining 75% vests in equal monthly installments during the 36 months following the first anniversary of the grant date.
Footnote F2
Includes 40,395 restricted common stock awards that were granted on July 7, 2022, of which, 25% vested on the first anniversary of the grant date and the remaining 75% vests in equal monthly installments during the 36 months following the first anniversary of the grant date.
Footnote F3
37,374 non-qualified stock option awards were granted on October 23, 2023, of which, 25% of the option vests on the first anniversary of the grant date and the remaining 75% vests in equal monthly installments during the 36 months following the first anniversary of the grant date.
SEC remarks
Exhibit List Exhibit 24 - Power of Attorney